Imatinib
- OralImatinibGlivec
Mechanism of Action
- Inhibits the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.
Clinical Use
- Indications
- First line treatment for chronic myeloid leukaemia
- Philadelphia chromosome positive acute lymphoblastic leukaemia
- Hypereosinophilic syndrome
- cKIT positive unresectable or metastatic gastrointestinal stromal tumours
- Adverse Effects
- Rash
- Fatigue
- Oedema
- Nausea / vomiting / diarrhoea
- Muscle cramping
- Peripheral neuropathy
- LFT derangement
- Myelosuppression - anaemia, neutropaenia, thrombocytopaenia